Advancements in On-Body Drug Delivery Systems: Overcoming Challenges and Driving Innovation
Advances in on-body delivery for high volume and viscous drugs, with strategies for optimising platforms from prototype through to clinical readiness.
Date
April 10th, 2025
Time
4pm (CET) / 10am (ET)
Presented by:
OVERVIEW

On-Body Drug Delivery Systems (OBDS) are transforming how medications are administered, offering innovative solutions for high-volume and viscous drug formulations where traditional autoinjectors often fall short. These systems combine advanced engineering with patient-centric design to improve treatment outcomes and adherence.

This webinar will explore the limitations of current drug delivery methods, focusing on challenges such as volume constraints, patient comfort, and adherence. Using the Sorrel OBDS platform as a case study, we will highlight its role in the development of the UDENYCA On-body injector, which has redefined delivery efficiency by significantly reducing administration times while maintaining usability and comfort.

 

Gain insights into the steps required to transition OBDS platforms from prototypes to clinical readiness, ensuring devices are optimised for both patient needs and regulatory requirements.

 

This session is ideal for professionals looking to deepen their understanding of OBDS technologies and their impact on the future of drug delivery.

Reserve Your Seat
Addressed Challenges
01Delivering high-volume or highly viscous drug formulations where conventional autoinjectors are unsuitable due to volume and pressure constraints. 
02Maintaining patient adherence when discomfort or extended administration times associated with certain delivery systems reduce compliance and satisfaction. 
03Navigating the technical and regulatory complexity of transitioning on-body delivery systems from engineering concept to market-ready commercial device. 
WHAT YOU WILL LEARN
01Gain an understanding of the technological advancements behind OBDS, focusing on solutions for high-volume and viscous subcutaneous drug delivery. 
02Learn practical steps and strategies for rapidly optimising an on-body delivery system platform to meet clinical readiness and regulatory requirements. 
03Explore how OBDS can enhance patient outcomes and support commercial differentiation through improved usability, comfort, and administration efficiency. 
SPEAKER
Dr. Greg Moakes, PHD
Executive Vice President, Business Development
Greg Moakes is Executive Vice President of Business Development for LTS Lohmann Device Technologies LTD. Greg holds a Ph.D. In Chemistry from the Georgia Institute of Technology and an MBA from Southern Methodist University. His career had been focused on drug delivery, first specializing in solid implant dosage formulations and more recently high volume subcutaneous delivery via On-body Delivery Systems.
Read More
Turn Registrants Into Relationships

Most registrants disappear after the session ends. We help you
open the right doors before, during, and after the webinar.

<span>By ticking this box, you consent to receiving communications from LTS related to this topic and other products or services within their portfolio</span>